Gilead Sciences Balance Sheet Health
Financial Health criteria checks 3/6
Gilead Sciences has a total shareholder equity of $18.4B and total debt of $24.4B, which brings its debt-to-equity ratio to 132.7%. Its total assets and total liabilities are $54.5B and $36.1B respectively. Gilead Sciences's EBIT is $11.3B making its interest coverage ratio 18.7. It has cash and short-term investments of $5.0B.
Key information
132.7%
Debt to equity ratio
US$24.41b
Debt
| Interest coverage ratio | 18.7x |
| Cash | US$5.04b |
| Equity | US$18.39b |
| Total liabilities | US$36.14b |
| Total assets | US$54.53b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GIS's short term assets ($13.1B) exceed its short term liabilities ($11.7B).
Long Term Liabilities: GIS's short term assets ($13.1B) do not cover its long term liabilities ($24.4B).
Debt to Equity History and Analysis
Debt Level: GIS's net debt to equity ratio (105.3%) is considered high.
Reducing Debt: GIS's debt to equity ratio has increased from 118.6% to 132.7% over the past 5 years.
Debt Coverage: GIS's debt is well covered by operating cash flow (41.1%).
Interest Coverage: GIS's interest payments on its debt are well covered by EBIT (18.7x coverage).